According to a recent market study published by Growth Market Reports, titled, “Global Biopharmaceutical Market by drug class type, by application, and by region: Size, Share, Trends and Opportunity Analysis, 2019-2030”, the market was valued at US$ 5,01,387.6 Million in 2021 and is expected to expand at a growth rate of 14.9% by 2030.

Biopharmaceuticals are types of drugs made by extracting proteins and nucleic acids directly from biological sources with the help of biotechnology. Biopharmaceuticals comprise proteins, living cells, sugars, nucleic acids, tissues, and a complex combination of different components. These drugs are widely used in the manufacture and development of vaccines, blood components, body cells and tissues, allergenic, and living cells used in cell therapies, gene therapies, and recombinant therapeutic proteins.

Get Sample Report @

The COVID-19 situation increased the demand for biopharmaceutical medication, as biopharmaceutical companies were actively involved in the development of vaccines to save the lives of COVID-19 patients. Biopharmaceutical companies were engaged in collaborations with research institutes that offered their expertise and resources in the research & development of vaccines. Furthermore, in 2020, research-based biopharmaceutical companies conducted around 5000 clinical trials for the investigation and development of vaccines during the pandemic. Thus, increasing demand for vaccine development to combat COVID-19 is boosting the sales of biopharmaceutical formulations, thus creating a positive impact on the growth of the market.

As per growth market reports industry, Anuradha More, & Sanket Lunawat, “The vaccines segment is projected to expand at a 15.4% CAGR during the forecast period. The growing government initiative and focus on the development of vaccines and the increasing prevalence of infectious diseases are projected to fuel the segment.

A supply chain is a network of companies, suppliers, manufacturers, and distributors involved in the creation and sale of a product to the final buyers. This network includes different activities, information, entities, people, and resources. Entities involved in the supply chain include manufacturers, vendors, warehouses, transportation firms, distribution centers, and retailers. The presence of major suppliers and wholesalers, adoption of technologies, availability of raw materials, and presence of an integrated logistics industry are some factors that strengthened the supply chain in developed regions.

Key Takeaways from the Study

The players in the global biopharmaceutical market include

  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • GSK plc
  • Bristol-Myers Squibb Company

The presence of competitive industry players who are focusing on increasing the R&D investment, engaged in a partnership with other players of biopharmaceutical formulation. For instance, Gilead Sciences entered into a partnership with Pfizer to expand its manufacturing facilities and supply biopharmaceutical formulations during the pandemic.

Based on drug class type, the global biopharmaceuticals market is segmented into monoclonal antibodies, interferon, colony-stimulating factor, erythropoietin, insulin, vaccines, growth hormones, and others. The vaccines segment is projected to expand at a 15.4% CAGR during the forecast period. The increase in government initiatives and focus on the development of vaccines and the increasing prevalence of infectious diseases are projected to fuel the segment.

The diabetes segment is expected to hold a 21.6% share of the market in 2021, due to the increasing prevalence of diabetes and rising initiatives by various health organizations to increase awareness about the disorder.

On the basis of region, the global biopharmaceutical market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The market in North America is anticipated to expand at a 15.2% CAGR during the forecast period due to the rising prevalence of chronic diseases and increasing investments in R&D activities in the US. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. The rising chronic diseases and the growing geriatric population are major factors projected to fuel the market share of the region.

Report Scope

Report Metric


Market Value in 2021

US$ 5,01,387.6 Million

Market Growth Rate (from 2022 to 2030)


Historical Data

2015 to 2020

Base Year


Forecast Period

2022 - 2030

Units Considered

Value (US$ Million)

Market Segments

By Drug Class Type, By Application, and By Region

Key Companies Profiled

F. Hoffmann-La Roche Ltd, Amgen Inc., AbbVie Inc., Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, GSK plc, Bristol-Myers Squibb Company

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Manufacturers and distributors.
  • Demand Side: Biopharmaceutical, Pharmaceutical Sectors
  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.
  • Associations and Industry Bodies: World Heart Federation, US Food and Drug Administration, National Health Expenditure.